Stockreport

Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain

Baudax Bio, Inc.  (BXRX) 
PDF ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing U.S. Commercial Launch Planned to Commence in Late April or Earl [Read more]